Extracellular Vesicles Derived from Embryonic Day 13 Fetal Mouse Dermal Fibroblasts Exhibit Potential Antifibrotic Activity
April 2026
in “
Research Square
”
extracellular vesicles embryonic day 13 fetal mouse dermal fibroblasts antifibrotic activity fibrotic activation human keloid-derived fibroblasts scarring fibrosis E13 dermal fibroblasts therapeutic strategies fibrotic skin diseases antifibrotic properties EVs E13 fibroblasts keloid scars skin fibrosis
TLDR E13 fetal mouse fibroblast vesicles may help reduce scarring.
The study explores the antifibrotic potential of extracellular vesicles (EVs) from embryonic day 13 (E13) fetal mouse dermal fibroblasts. These EVs were effective in suppressing fibrotic activation in both E17 fascia fibroblasts and human keloid-derived fibroblasts, which are linked to scarring and fibrosis. In contrast, EVs from E17 and adult fibroblasts increased fibrotic responses. The findings suggest that E13 dermal fibroblasts have intrinsic antifibrotic properties transferable via EVs, offering potential therapeutic strategies for human scars and fibrotic skin diseases. The study also notes the importance of determining the optimal EV dosage, as higher doses may not achieve the desired antifibrotic effects. Despite challenges in large-scale collection and potential risks in human therapy, E13-derived EVs show promise for future antifibrotic treatments, emphasizing the need to identify specific antifibrotic factors within these EVs.
